VJHemOnc is committed to improving our service to you

ASH 2019 | TOTAL Therapy 7: high response rates in high risk NDMM to daratumumab

VJHemOnc is committed to improving our service to you

Faith Davies

The TOTAL Therapy (TT) approach has significantly improved the outcome of multiple myeloma (MM) by combining new drugs with a regimen that comprises induction, tandem autologous stem cell transplantation (ASCT), consolidation and maintenance. In the TT7 study, daratumumab was induced during all phases of therapy for high risk newly diagnosed MM, including immune consolidation early post-ASCT. Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Medical Center, New York, NY, discusses the early results of TT7, pointing to increased response rates of newly diagnosed high risk MM to daratumumab. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter